Loading stock data…
Spyre Therapeutics, Inc. (SYRE)
$90.79+1.81 (+2.03%)
Market ClosedLast close Sep 8
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Spyre Therapeutics, Inc. in the Healthcare sector is trading at $90.79 with a market capitalization of $7.8B. Wall Street consensus targets $119.69 (13 analysts), implying a +31.8% move over the next 12 months. The stock is currently 18% below its 52-week high of $110.17, remaining 46.5% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 24 is oversold, raising the odds of a near-term bounce. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +31.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 24) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$81.64M↓ | -$75.64M↓ | -$57.17M↓ | -$56.89M↓ | -$51.94M |
| Net Income | -$36.20M↑ | -$69.00M↓ | -$62.53M↓ | -$11.18M↑ | -$36.72M |
Peer Comparison
JNJUNHPFE
Fundamentals
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$7.85B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
3.00
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-16.25%
Volume
Today's trading volume
1.25M
Recent News
Spyre Therapeutics (SYRE) Down 16.6% Since Last Earnings Report: Can It Rebound?
Spyre Therapeutics (SYRE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Spyre (SYRE) Fell 13% on Its Weakest Program. Its Best One Just Worked
Spyre Therapeutics, Inc. (NASDAQ:SYRE) fell 13% to $94 on August 26, 2026, but the sell-off sharply overreacted to the underlying data. The company’s SPY072 asset, tested in a rheumatoid arthritis sub-study of the Phase 2 SKYWAY trial reported August 25, cleared statistical significance versus placebo on one or more of the primary DAS28-CRP endpoints and […]
Spyre Therapeutics Plunges; Why Analysts Aren't Sweating
Spyre Therapeutics took a hit Wednesday after its experimental rheumatoid arthritis treatment failed to pass muster in midstage testing.
SYRE Stock Sinks After Mixed SKYWAY Study Data in Rheumatoid Arthritis
Spyre's SPY072 shows activity in RA, but a smaller-than-expected benefit shifts its focus toward broader autoimmune uses and combinations.
Spyre tumbles as immune drug misses mark in rheumatoid arthritis
The results erased more than $1 billion in market value and raised questions about how impactful drugs that block the TL1A protein might be against the condition.